SCHEMBL3246718

SCHEMBL3246718

Nc1csc(-c2ccncc2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 1/20 0.47
DBF4 Q9UBU7 1/20 0.47
DYRK1B Q9Y463 4/20 0.45
MAPT P10636 5/20 0.44
LMNA P02545 3/20 0.44
ALDH1A1 P00352 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MEN1 O00255 1/20 0.44
CYP2D6 P10635 1/20 0.44
CHRM1 P11229 1/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
KMT2A Q03164 1/20 0.44
KCNA1 Q09470 1/20 0.44
DYRK1A Q13627 4/20 0.44
NPC1 O15118 3/20 0.40
RAB9A P51151 2/20 0.40
GFER P55789 2/20 0.40
GAA P10253 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28148464 0.80 DYRK1B (0.69) DYRK1BALDH1A1SMN1; SMN2MEN1CYP2D6
SCHEMBL4489979 0.80 MAOA (0.48) DYRK1BMAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL28016402 0.79 DYRK1B (0.35) DYRK1BDYRK1A
SCHEMBL12766038 0.77 PRKCZ (0.53) DYRK1BMAPTALDH1A1SMN1; SMN2CYP2D6
SCHEMBL28318687 0.77 DYRK1A (0.59) CDC7DBF4DYRK1BMAPTLMNA
SCHEMBL3082747 0.77 MAPT (0.44) MAPTLMNAALDH1A1SMN1; SMN2MEN1
SCHEMBL10583935 0.77 IKBKB (0.46) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL19990277 0.77 HSD17B1 (0.55) ALDH1A1MEN1KMT2AHSD17B10CYP3A4
SCHEMBL28175721 0.77 IKBKB (0.46) MAPTALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL4474410 0.76 MAPK13 (0.48) CDC7DBF4DYRK1BMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1558607-B1 COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES VERTEX PHARMA (US) 2010-05-05 EP disclosed
EP-1558607-B1 COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES VERTEX PHARMA (US) 2010-05-05 EP disclosed
CN-1732164-A Compositions useful as inhibitors of ROCK and other protein kinases VERTEX PHARMA (US) 2006-02-08 CN disclosed
EP-1558607-A1 COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES Vertex Pharmaceuticals Incorporated (US) 2005-08-03 EP disclosed
US-20040122016-A1 Compositions useful as inhibitors of rock and other protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2004-06-24 US disclosed
WO-2004041813-A1 COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-05-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122016-A1 Compositions useful as inhibitors of rock and other protein kinases ROCK1, ROCK2, PRKCH CDC7 300/4885DBF4 2543/4885DYRK1B 762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.